Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab botidotin - Klus Pharma

Next Previous
Drug Profile

Trastuzumab botidotin - Klus Pharma

Alternative Names: A-166

Latest Information Update: 31 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Klus Pharma
  • Developer Klus Pharma; Sichuan Kelun-Biotech Biopharmaceutical
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered HER2 positive breast cancer
  • Phase I/II Solid tumours
  • Phase I Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Urogenital cancer

Most Recent Events

  • 31 Oct 2025 Sichuan Kelun Biotech-Biopharmaceutical has patent protection for use of an anti-HER2 antibody-drug conjugate for cancer in USA and China
  • 30 Oct 2025 Sichuan Kelun-Biotech Biopharmaceutical plans to launch Trastuzumab botidotin for HER2-positive breast cancer in China in the second half of 2025
  • 21 Oct 2025 Efficacy and adverse events data from phase III trial in Breast cancer released by Sichuan Kelun-Biotech Biopharmaceutical

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top